ClinicalTrialsFinder
RecruitingPhase 1NCT07546760

A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234

A Phase I, Multicentre, Single-Dose, Non-Randomised, Open-Label, Parallel-Group Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD9550 and AZD6234

Sponsor

AstraZeneca

Enrollment

28 participants

Start Date

Mar 20, 2026

Study Type

INTERVENTIONAL

Conditions

Hepatic Impairment

Summary

The purpose of this study is to examine the safety and tolerability of AZD6234 and AZD9550 in participants with hepatic impairment and participants with normal hepatic function.

Eligibility

Min Age: 18 YearsMax Age: 85 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called AZD6234 and a drug called AZD9550 for people with hepatic impairment. The study is currently recruiting participants at 4 locations. People eligible for this study include aged 18 Years to 85 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAZD6234

Single subcutaneous dose of AZD6234 in participants from all groups

DRUGAZD9550

Single subcutaneous dose of AZD9550 in participants from all groups

Locations(4)

Research Site

Chandler, Arizona, United States

Research Site

Rialto, California, United States

Research Site

Miami Lakes, Florida, United States

Research Site

San Antonio, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07546760

Related Trials

Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease

NCT050454821 location

A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Normal Hepatic Function and Participants With Hepatic Impairment

NCT07643155

A Study to Test How BI 1291583 is Taken up in the Blood of People With and Without Liver Problems

NCT070233543 locations

A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib

NCT071441114 locations

Comparative PK Assessment Study of Casdatifan in Moderate Hepatically Impaired Participants Versus Matched Participants With Normal Hepatic Function

NCT07751250